Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Immuneering A | IMRX | Dec 31, 2024 | 2.20 | -2.22 |
Immunic | IMUX | Dec 31, 2024 | 1.00 | -2.91 |
ImmunityBio | IBRX | Dec 31, 2024 | 2.56 | -4.48 |
Immunocore ADR | IMCR | Dec 31, 2024 | 29.50 | +1.62 |
Immunome | IMNM | Dec 31, 2024 | 10.62 | +3.31 |
ImmunoPrecise Antibodies | IPA | Dec 31, 2024 | 0.41 | +0.66 |
Immunovant | IMVT | Dec 31, 2024 | 24.77 | +3.73 |
Immutep ADR | IMMP | Dec 31, 2024 | 2.17 | +4.33 |
Imperial Oil | IMO | Dec 31, 2024 | 61.60 | +0.77 |
Imperial Petroleum | IMPP | Dec 31, 2024 | 3.01 | -1.95 |
Imperial Petroleum A Pref | IMPPP | Dec 31, 2024 | 24.76 | +0.04 |
Impinj | PI | Dec 31, 2024 | 145.26 | -0.91 |
Imunon | IMNN | Dec 31, 2024 | 0.95 | +15.15 |
IN8bio | INAB | Dec 31, 2024 | 0.26 | -4.39 |
Inari Medical | NARI | Dec 31, 2024 | 51.05 | -1.69 |
Incannex Healthcare ADR | IXHL | Dec 31, 2024 | 2.12 | +1.44 |
Inception Growth Acquisition | IGTA | Dec 31, 2024 | 11.75 | 0.00 |
Inception Growth Acquisition Unit | IGTAU | Dec 31, 2024 | 12.00 | 0.00 |
Income Opportunity Realty Investors | IOR | Dec 31, 2024 | 18.00 | +0.98 |
Incyte | INCY | Dec 31, 2024 | 69.07 | +0.95 |
Indaptus Therapeutics | INDP | Dec 31, 2024 | 0.84 | -3.69 |
Independence Realty Trust | IRT | Dec 31, 2024 | 19.84 | +0.20 |
Independent Bank | IBCP | Dec 31, 2024 | 34.83 | +0.26 |
Independent Bank | INDB | Dec 31, 2024 | 64.19 | +0.12 |
Independent Bank Group | IBTX | Dec 31, 2024 | 60.67 | +0.46 |
India Bull 3X Direxion | INDL | Dec 31, 2024 | 59.57 | +0.02 |
India Consumer Egshares | INCO | Dec 31, 2024 | 64.43 | +0.23 |
India Earnings Wisdomtree | EPI | Dec 31, 2024 | 45.27 | +0.40 |
India Fund | IFN | Dec 31, 2024 | 15.75 | +0.25 |
India Powershares | PIN | Dec 31, 2024 | 25.77 | +0.04 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.